Home › Funds › BAKER BROS. ADVISORS LP › ROIV

BAKER BROS. ADVISORS LP position in ROIV

ROIVANT SCIENCES LTD · Health Care

BAKER BROS. ADVISORS LP reported holding 4,716,831 shares of ROIV (ROIVANT SCIENCES LTD) in its Q2 2026 13F filing — a position valued at US$166.9M, representing 0.87% of its reported portfolio and ranking #18 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed ROIV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)4.72M sh
Reported value held$166.93M
Portfolio Weight0.87%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's ROIV position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in ROIV in Q3 2023 at 11,877,171 shares (US$138.7M). The position peaked in Q2 2026 at 4,716,831 shares, worth US$166.9M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 5 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 4,716,831 shares valued at US$166.9M — a reduction of -150,892 shares quarter over quarter.. Notable position changes include a 36% trim in Q4 2023 (shares fell 6% over the following quarter), a 62% trim in Q2 2024 (shares rose 9% over the following quarter), a 47% increase in Q4 2025 (shares rose 28% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 11.88M $138.73M New
Q4 2023 7.59M $85.27M Reduce
Q1 2024 7.41M $78.14M Reduce
Q2 2024 2.80M $29.58M Reduce
Q3 2024 2.80M $32.30M Hold
Q4 2024 3.77M $44.57M Add
Q1 2025 3.77M $38.02M Hold
Q2 2025 3.77M $42.46M Hold
Q3 2025 3.77M $57.01M Hold
Q4 2025 5.56M $120.54M Add
Q1 2026 4.87M $134.84M Reduce
Q2 2026 4.72M $166.93M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ROIV and 13F data

ROIV (ROIVANT SCIENCES LTD) is a Health Care company. 63 other funds we track also report a position in ROIV — the largest reported positions include QVT Financial LP (US$839.6M), Farallon Capital Management (US$506.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$506.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ROIV

All ROIV fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held ROIV?

BAKER BROS. ADVISORS LP has disclosed ROIV holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in ROIV?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 4.72M shares of ROIV (ROIVANT SCIENCES LTD), valued at $166.93M, representing 0.87% of its reported portfolio and ranking #18.

Has BAKER BROS. ADVISORS LP been buying or selling ROIV?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP reduced its position in ROIV. The position peaked in Q2 2026 at 4.72M shares.

Which other funds hold ROIV?

Other major institutional holders of ROIV include QVT Financial LP, Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., among 63 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.